Literature DB >> 1568457

Acquisition of growth autonomy and tumorigenicity by an interleukin 6-dependent human myeloma cell line transfected with interleukin 6 cDNA.

Y Okuno1, T Takahashi, A Suzuki, M Fukumoto, K Nakamura, H Fukui, Y Koishihara, Y Ohsugi, H Imura.   

Abstract

In human multiple myeloma, an autocrine growth mechanism through interleukin 6 (IL-6) has been advocated. However, growth of myeloma cells in vitro is poor except for established cell lines, and IL-6 autocrine growth is quite rare in myeloma cell lines. In the present study, we devised a model of IL-6 autocrine growth in vitro by transfecting IL-6 cDNA into a human myeloma cell line that had a proliferative response to IL-6 but did not produce IL-6. After IL-6 transfection, the cells proliferated in culture media without IL-6, and their growth rate was elevated at higher cell densities. IL-6 was detected by enzyme-linked immunosorbent assay in the culture media of the transfectants. IL-6 mRNA was distinctly expressed in these cells when analyzed by Northern blotting. The growth of the transfectants was definitely inhibited by anti-IL-6 or anti-IL-6 receptor monoclonal antibodies. Furthermore, the transfectants were successfully transplanted to nude mice. These results indicate that the myeloma cells obtained growth autonomy in vitro through IL-6 and tumorigenicity in vivo, after IL-6 transfection.

Entities:  

Mesh:

Substances:

Year:  1992        PMID: 1568457

Source DB:  PubMed          Journal:  Exp Hematol        ISSN: 0301-472X            Impact factor:   3.084


  5 in total

1.  Interleukin-6 gene ablation in a transgenic mouse model of malignant skin melanoma.

Authors:  Verena von Felbert; Francisco Córdoba; Jakob Weissenberger; Claudio Vallan; Masashi Kato; Izumi Nakashima; Lasse Roger Braathen; Joachim Weis
Journal:  Am J Pathol       Date:  2005-03       Impact factor: 4.307

2.  Accelerated in vivo growth of prostate tumors that up-regulate interleukin-6 is associated with reduced retinoblastoma protein expression and activation of the mitogen-activated protein kinase pathway.

Authors:  Hannes Steiner; Sonia Godoy-Tundidor; Hermann Rogatsch; Andreas P Berger; Dietmar Fuchs; Barbara Comuzzi; Georg Bartsch; Alfred Hobisch; Zoran Culig
Journal:  Am J Pathol       Date:  2003-02       Impact factor: 4.307

3.  Disruption by interferon-alpha of an autocrine interleukin-6 growth loop in IL-6-dependent U266 myeloma cells by homologous and heterologous down-regulation of the IL-6 receptor alpha- and beta-chains.

Authors:  M Schwabe; A T Brini; M C Bosco; F Rubboli; M Egawa; J Zhao; G L Princler; H F Kung
Journal:  J Clin Invest       Date:  1994-12       Impact factor: 14.808

4.  Interleukin-6 undergoes transition from paracrine growth inhibitor to autocrine stimulator during human melanoma progression.

Authors:  C Lu; R S Kerbel
Journal:  J Cell Biol       Date:  1993-03       Impact factor: 10.539

5.  Mouse anti-human interleukin-6 receptor monoclonal antibody inhibits proliferation of fresh human myeloma cells in vitro.

Authors:  H Goto; C Shimazaki; T Tatsumi; N Yamagata; T Hirata; E Ashihara; N Oku; T Inaba; N Fujita; Y Koishihara
Journal:  Jpn J Cancer Res       Date:  1994-09
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.